Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon for Treatment-Free Remission in CML with Sustained Deep Molecular Response
KCT0006858Phase 2Recruiting
- Sponsor
- PharmaEssentia
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in chronic myelogenous leukemia (CML), sponsored by PharmaEssentia. Started May 2022; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on KCT0006858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006858.